Carlo Boutton

TLDR

Carlo Boutton is Interim CEO of Biotalys, a Ghent-based VIB spinoff developing protein-based biocontrol agents for crop protection, listed on Euronext Brussels.

Overview

Boutton holds an MSc and PhD from KU Leuven, researching protein behavior under high electromagnetic fields, and brings more than 20 years of antibody and biochemistry leadership. He joined Biotalys in May 2022 as Chief Scientific Officer, having previously served as Global Head of Innovation for Large Molecules Research at Sanofi and held scientific leadership roles at Ablynx (now Sanofi) and Tibotec (a Johnson and Johnson subsidiary). He assumed the interim CEO role following the departure of Kevin Helash.

Career History

• Tibotec (J&J), anti-HIV and anti-HCV drug discovery
• Ablynx (now Sanofi), bioinformatics and protein modelling
• Sanofi, Global Head of Innovation Large Molecules Research
• Biotalys, CSO (May 2022), Interim CEO (2026)